Two-year longitudinal follow-up of visual illusions and hallucinations in Parkinson's disease.
Evolution
Hallucinations
Illusions
Ophthalmology
Prognosis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
16
12
2021
accepted:
08
03
2022
revised:
07
03
2022
pubmed:
18
3
2022
medline:
22
7
2022
entrez:
17
3
2022
Statut:
ppublish
Résumé
Previous longitudinal studies assessing visual hallucinations in Parkinson's disease (PD) have not specifically considered the respective evolution of visual illusions (VI) and visual hallucinations (VH), neither did they assess the role of ocular pathology on the evolution of those manifestations. We aimed to determine whether VI evolve towards VH along the time in PD, and whether ophthalmological treatment may have a positive effect on the prognosis of those visuo-perceptive manifestations. PD patients from a previous cohort [PD with VI (n = 26), PD with VH (n = 28), and PD without VI or VH (n = 28)] were contacted by phone 2 years later and questioned regarding the current presence of VI or VH, any current visual complaints, and the occurrence of any ophthalmological or antipsychotic treatment during the 2-year period, as well as any dopatherapy adjustment. Among PD-VI patients, 43% normalized, 48% remained PD-VI, 9% evolved towards coexisting VI and VH, and none converted to pure VH. Among PD-VH patients, 42% normalized, 32% remained PD-VH, 21% evolved towards coexisting VI and VH, and only 5% converted to pure VI. At follow-up, visual complaints remained greater among PD-VI and PD-VH compared to controls (p = 0.005). Among PD-VI and PD-VH who became control at follow-up, 35% received ophthalmologic treatment, 29% antipsychotic treatment, and 23% a dopatherapy reduction. PD Patients with VI do not necessarily evolve towards VH over time, and ophthalmological treatment may have a positive effect on the prognosis of those visuo-perceptive manifestations in PD similar to antipsychotic treatment and dopatherapy adjustment. clinicaltrials.gov number NCT01114321.
Sections du résumé
BACKGROUND
BACKGROUND
Previous longitudinal studies assessing visual hallucinations in Parkinson's disease (PD) have not specifically considered the respective evolution of visual illusions (VI) and visual hallucinations (VH), neither did they assess the role of ocular pathology on the evolution of those manifestations.
OBJECTIVE
OBJECTIVE
We aimed to determine whether VI evolve towards VH along the time in PD, and whether ophthalmological treatment may have a positive effect on the prognosis of those visuo-perceptive manifestations.
METHODS
METHODS
PD patients from a previous cohort [PD with VI (n = 26), PD with VH (n = 28), and PD without VI or VH (n = 28)] were contacted by phone 2 years later and questioned regarding the current presence of VI or VH, any current visual complaints, and the occurrence of any ophthalmological or antipsychotic treatment during the 2-year period, as well as any dopatherapy adjustment.
RESULTS
RESULTS
Among PD-VI patients, 43% normalized, 48% remained PD-VI, 9% evolved towards coexisting VI and VH, and none converted to pure VH. Among PD-VH patients, 42% normalized, 32% remained PD-VH, 21% evolved towards coexisting VI and VH, and only 5% converted to pure VI. At follow-up, visual complaints remained greater among PD-VI and PD-VH compared to controls (p = 0.005). Among PD-VI and PD-VH who became control at follow-up, 35% received ophthalmologic treatment, 29% antipsychotic treatment, and 23% a dopatherapy reduction.
CONCLUSION
CONCLUSIONS
PD Patients with VI do not necessarily evolve towards VH over time, and ophthalmological treatment may have a positive effect on the prognosis of those visuo-perceptive manifestations in PD similar to antipsychotic treatment and dopatherapy adjustment.
TRIAL REGISTRATION
BACKGROUND
clinicaltrials.gov number NCT01114321.
Identifiants
pubmed: 35296961
doi: 10.1007/s00415-022-11074-2
pii: 10.1007/s00415-022-11074-2
doi:
Substances chimiques
Antipsychotic Agents
0
Banques de données
ClinicalTrials.gov
['NCT01114321']
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
4546-4554Subventions
Organisme : Fondation de France
ID : 76354
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289:12–17. https://doi.org/10.1016/j.jns.2009.08.014
doi: 10.1016/j.jns.2009.08.014
pubmed: 19740486
Marques A, Beze S, Pereira B et al (2020) Visual hallucinations and illusions in Parkinson’s disease: the role of ocular pathology. J Neurol. https://doi.org/10.1007/s00415-020-09925-x
doi: 10.1007/s00415-020-09925-x
pubmed: 32447550
Marques A, Beze S, Lambert C et al (2021) Psycho-sensory modalities of visual hallucinations and illusions in Parkinson’s disease. Revue Neurologique. https://doi.org/10.1016/j.neurol.2021.04.007
doi: 10.1016/j.neurol.2021.04.007
pubmed: 34238577
Marques A, Taylor NL, Roquet D et al (2021) Structural and functional correlates of hallucinations and illusions in Parkinson’s disease. J Parkinsons Dis. https://doi.org/10.3233/JPD-212838
doi: 10.3233/JPD-212838
de Maindreville AD, Fénelon G, Mahieux F (2005) Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord 20:212–217. https://doi.org/10.1002/mds.20263
doi: 10.1002/mds.20263
pubmed: 15390044
Goetz CG, Leurgans S, Pappert EJ et al (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57:2078–2082. https://doi.org/10.1212/wnl.57.11.2078
doi: 10.1212/wnl.57.11.2078
pubmed: 11739829
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 55:181–184
doi: 10.1136/jnnp.55.3.181
Nasreddine ZS, Phillips NA, Bédirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
doi: 10.1111/j.1532-5415.2005.53221.x
pubmed: 15817019
Visser M, Verbaan D, van Rooden SM et al (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22:2221–2228. https://doi.org/10.1002/mds.21696
doi: 10.1002/mds.21696
pubmed: 17712843
Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord 22:41–47. https://doi.org/10.1002/mds.21198
doi: 10.1002/mds.21198
pubmed: 17115387
Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429
doi: 10.1002/mds.23429
pubmed: 21069833
Borm CDJM, Visser F, Werkmann M et al (2020) Seeing ophthalmologic problems in Parkinson disease: results of a visual impairment questionnaire. Neurology 94:e1539–e1547. https://doi.org/10.1212/WNL.0000000000009214
doi: 10.1212/WNL.0000000000009214
pubmed: 32161030
pmcid: 7251522
O’Brien J, Taylor JP, Ballard C et al (2020) Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. J Neurol Neurosurg Psychiatry 91:512–519. https://doi.org/10.1136/jnnp-2019-322702
doi: 10.1136/jnnp-2019-322702
pubmed: 32213570
Matsui H, Udaka F, Tamura A et al (2006) Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. J Geriatr Psychiatry Neurol 19:36–40. https://doi.org/10.1177/0891988705284739
doi: 10.1177/0891988705284739
pubmed: 16449759
Smith CS, Nichols J, Riaz KM (2018) Remission of Charles Bonnet syndrome after cataract extraction. Can J Ophthalmol 53:e221–e222. https://doi.org/10.1016/j.jcjo.2018.01.036
doi: 10.1016/j.jcjo.2018.01.036
pubmed: 30502996
Osa AA, Bowen TJ, Whitson JT (2020) Charles bonnet syndrome in a patient with Parkinson’s disease and bilateral posterior capsule opacification. Int Med Case Rep J 13:7–10. https://doi.org/10.2147/IMCRJ.S218687
doi: 10.2147/IMCRJ.S218687
pubmed: 32021492
pmcid: 6959487
Matsui H, Udaka F, Oda M et al (2004) Two cases of Parkinson’s disease in which visual hallucinations disappeared after cataract surgery. No To Shinkei 56:351–354
pubmed: 15237728
Hamedani AG, Abraham DS, Maguire MG, Willis AW (2020) Visual impairment is more common in Parkinson’s disease and is a risk factor for poor health outcomes. Mov Disord 35:1542–1549. https://doi.org/10.1002/mds.28182
doi: 10.1002/mds.28182
pubmed: 32662528
pmcid: 8183672
Sloan FA, Yashkin AP, Chen Y (2014) Gaps in receipt of regular eye examinations among medicare beneficiaries diagnosed with diabetes or chronic eye diseases. Ophthalmology 121:2452–2460. https://doi.org/10.1016/j.ophtha.2014.07.020
doi: 10.1016/j.ophtha.2014.07.020
pubmed: 25208856
Ekker MS, Janssen S, Seppi K et al (2017) Ocular and visual disorders in Parkinson’s disease: common but frequently overlooked. Parkinsonism Relat Disord 40:1–10. https://doi.org/10.1016/j.parkreldis.2017.02.014
doi: 10.1016/j.parkreldis.2017.02.014
pubmed: 28284903
Stagg BC, Ehrlich JR, Choi H, Levine DA (2019) Association of cognitive impairment and dementia with receipt of cataract surgery among community-dwelling medicare beneficiaries. JAMA Ophthalmol 137:114–117. https://doi.org/10.1001/jamaophthalmol.2018.5138
doi: 10.1001/jamaophthalmol.2018.5138
pubmed: 30422225